Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Immunome (IMNM) has issued an update.
Bob Lapetina is set to depart from his executive roles at Immunome, Inc. on May 10, 2024, to explore new opportunities, leaving behind no company disputes. Following his exit, Max Rosett will step up as the new principal accounting officer. Bringing a diverse background, including a tenure at Morphimmune, Inc. and experience at Google and the Boston Consulting Group, Rosett’s appointment consolidates his financial leadership within Immunome, underlined by his recent role as Interim CFO and EVP of Operations. This strategic shift in the financial department signals continuous evolution in the company’s executive suite.
Learn more about IMNM stock on TipRanks’ Stock Analysis page.